JP2023546205A - コンジュゲートｔｌｒ７およびｎｏｄ２アゴニスト - Google Patents

コンジュゲートｔｌｒ７およびｎｏｄ２アゴニスト Download PDF

Info

Publication number
JP2023546205A
JP2023546205A JP2023524121A JP2023524121A JP2023546205A JP 2023546205 A JP2023546205 A JP 2023546205A JP 2023524121 A JP2023524121 A JP 2023524121A JP 2023524121 A JP2023524121 A JP 2023524121A JP 2023546205 A JP2023546205 A JP 2023546205A
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
mmol
compound
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023524121A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546205A5 (https=
Inventor
ジャコピン ジーガ
グゼリ サモ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Univerza Ljubljana v Fakulteta za Farmazijo
Original Assignee
Univerza Ljubljana v Fakulteta za Farmazijo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univerza Ljubljana v Fakulteta za Farmazijo filed Critical Univerza Ljubljana v Fakulteta za Farmazijo
Publication of JP2023546205A publication Critical patent/JP2023546205A/ja
Publication of JP2023546205A5 publication Critical patent/JP2023546205A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023524121A 2020-10-21 2021-10-20 コンジュゲートｔｌｒ７およびｎｏｄ２アゴニスト Pending JP2023546205A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
LU102145 2020-10-21
LULU102145 2020-10-21
PCT/EP2021/079141 WO2022084417A1 (en) 2020-10-21 2021-10-20 Conjugated tlr7 and nod2 agonists

Publications (2)

Publication Number Publication Date
JP2023546205A true JP2023546205A (ja) 2023-11-01
JP2023546205A5 JP2023546205A5 (https=) 2024-09-06

Family

ID=74175904

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023524121A Pending JP2023546205A (ja) 2020-10-21 2021-10-20 コンジュゲートｔｌｒ７およびｎｏｄ２アゴニスト

Country Status (7)

Country Link
US (1) US20230382886A1 (https=)
EP (1) EP4232094A1 (https=)
JP (1) JP2023546205A (https=)
CN (1) CN116600830A (https=)
AU (1) AU2021363606A1 (https=)
CA (1) CA3196221A1 (https=)
WO (1) WO2022084417A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024102639A1 (en) * 2022-11-08 2024-05-16 The Scripps Research Institute N-arylpyrazole nod2 agonists as promoters of immune checkpoint inhibitor therapy
WO2025040743A1 (en) * 2023-08-22 2025-02-27 Univerza V Ljubljani Conjugated tlr7 and rig-i agonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010518082A (ja) * 2007-02-07 2010-05-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 合成ｔｌｒアゴニストの結合体およびそのための使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006242920A1 (en) 2005-05-04 2006-11-09 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as Toll-Like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
US8138172B2 (en) 2006-07-05 2012-03-20 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of TLR7
BRPI0917013A2 (pt) 2008-08-11 2016-02-16 Glaxosmithkline Llc métodos para tratar doenças alérgicas e outras condições inflamatórias, e para tratar ou prevenir doença, composto, composição farmacêutica, e, uso de um composto
KR20110117705A (ko) 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
AU2011247358B2 (en) 2010-04-30 2014-10-30 Urogen Pharma Ltd. Phospholipid drug analogs
WO2012038058A1 (en) 2010-09-21 2012-03-29 Telormedix Sa Treatment of conditions by toll-like receptor modulators
US10471139B2 (en) * 2013-08-15 2019-11-12 The University Of Kansas Toll-like receptor agonists
AU2017318601B2 (en) * 2016-09-02 2020-09-03 Gilead Sciences, Inc. Toll like receptor modulator compounds
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
WO2019197598A1 (en) 2018-04-13 2019-10-17 Glaxosmithkline Biologicals Sa Tlr7 and / or tlr8 agonists
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010518082A (ja) * 2007-02-07 2010-05-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 合成ｔｌｒアゴニストの結合体およびそのための使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EBIOMEDICINE, vol. 58, JPN6025031834, 30 July 2020 (2020-07-30), pages 102922, ISSN: 0005660157 *
J． MED. CHEM., vol. 61, JPN6025031835, 2018, pages 2707 - 2724, ISSN: 0005660158 *

Also Published As

Publication number Publication date
AU2021363606A9 (en) 2025-01-09
AU2021363606A1 (en) 2023-06-01
US20230382886A1 (en) 2023-11-30
CN116600830A (zh) 2023-08-15
WO2022084417A1 (en) 2022-04-28
CA3196221A1 (en) 2022-04-28
EP4232094A1 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
CN106232599B (zh) 4-氨基-咪唑并喹啉化合物
JP6769976B2 (ja) ピリミジン化合物
US9567336B2 (en) Conjugated TLR7 and/or TLR8 and TLR2 agonists
CN108794422B (zh) 作为pd-l1抑制剂的杂环类化合物
JP6521977B2 (ja) 免疫調節剤としての１，２，４−オキサジアゾール誘導体
US9295732B2 (en) Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
US10640520B2 (en) Boronic acid derivatives
EP3366289A1 (en) Cyclic peptidomimetic compounds as immunomodulators
CN110382508A (zh) 用于抑制精氨酸酶活性的组合物和方法
CN113150016A (zh) 用于抑制精氨酸酶活性的组合物和方法
JP2013040209A (ja) Ｔｌｒアゴニスト
EP3261443A1 (en) Desacetoxytubulysin h and analogs thereof
JP2023546205A (ja) コンジュゲートｔｌｒ７およびｎｏｄ２アゴニスト
CN120457136A (zh) Sting促效剂
EP3389643B1 (en) Novel muramyl peptide derivative compound, synthesis and uses thereof
JP2026016830A (ja) 合成プロセス及び中間体
EP2769738B1 (en) Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
US10927147B2 (en) Muramyl peptide derivative compound, synthesis and uses thereof
CA2460646A1 (en) Antibacterial macrocycles
JP2017528514A (ja) 新規化合物
JP2017528514A5 (https=)
WO2025093657A1 (en) Conjugated tlr7 and tlr4 agonists
WO2025040743A1 (en) Conjugated tlr7 and rig-i agonists
CN112512590A (zh) Tlr7肽缀合物
Wu Modulators of Toll-like Receptors-4 and-2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260423